Needham analyst Gil Blum has maintained their bullish stance on NRIX stock, giving a Buy rating yesterday.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Gil Blum’s rating is based on Nurix Therapeutics’ strategic advancements and promising pipeline developments. The company is on track to initiate pivotal studies for bexobrutideg in relapsed/refractory chronic lymphocytic leukemia (CLL) by the end of the fourth quarter of 2025, which is a significant milestone. Additionally, Nurix plans to provide several updates across its pipeline, including initial clinical data for NX-1607 and updated results for bexobrutideg, which could enhance investor confidence.
Furthermore, the planned open-label study for third-line and beyond CLL, along with a confirmatory study in the second-line post-BTK inhibitor setting, demonstrates a robust clinical strategy. The inclusion of various comparator arms could potentially expedite enrollment, showcasing the company’s proactive approach. With a strong financial position, ending the third quarter of 2025 with $429 million, Nurix is well-positioned to advance its clinical programs, supporting the Buy rating.
In another report released yesterday, Oppenheimer also reiterated a Buy rating on the stock with a $28.00 price target.